Fig. 8 | Scientific Reports

Fig. 8

From: Enhanced efficacy of combined VEGFR peptide–drug conjugate and anti-PD-1 antibody in treating hepatocellular carcinoma

Fig. 8

Effects of QR-KLU combined with anti-PD-1 antibody on the immune cells and immune factors in subcutaneous Hepa1–6 liver tumors in mice (n = 6). (A) Representative immunohistochemistry staining images of CD4+ and CD8+ cells (scale bar = 20 μm). (B) Determination of the number of CD8+ cells using flow cytometry. (C) Bar graph demonstrating TNF-α expression levels. (D) Bar graph demonstrating IFN-γ expression levels. (E) Bar graph demonstrating IL-2 expression levels. (F) Bar graph demonstrating IL-10 expression levels. α-SMA α-smooth muscle actin, CD; IFN-γ interferon-γ, PD-1 programmed cell death receptor-1, QR-KLU peptide (QR)–drug (KLU) conjugate, TNF-α tumor necrosis factor-α, VEGF vascular endothelial growth factor.

Back to article page